Quality assessment of clinical practice guidelines on tic disorders with AGREE II instrument

Abstract

To assess the methodological quality of existing clinical practice guidelines (CPGs) on the treatment of tic disorders (TDs) using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) instrument and summarize the guideline recommendations. Five CPGs met our inclusion criteria. The mean percentages for the AGREE II domain scores were: scope and purpose 83.33% (95% confidence interval [CI], 77.78–94.44%), stakeholder involvement 62.22% (95% CI, 38.89–94.44%), rigor of development 47.08% (95% CI, 6.25–83.33%), clarity of presentation 87.78% (95% CI, 72.22–94.44%), applicability 56.67% (95% CI, 33.33–87.50%), and editorial independence 46.67% (95% CI, 8.33–91.67%). There were large differences among the five CPGs concerning the categorization of evidence and recommendations. The recommendations for drug therapy were similar in all five CPGs, although there was controversy in certain areas. The methodological quality of CPGs for TDs was acceptable in terms of scope and purpose, stakeholder involvement, and clarity of presentation. However, CPG developers need to pay more attention to rigorous development processes, applicability, and editorial independence. Developers of future CPGs should improve adherence to the AGREE II guidelines. In addition, high quality studies on the treatment of TDs are needed to provide more evidence for developing guidelines.